Clinical factors associated with outcomes among patients receiving second-line therapy for advanced NSCLC

Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:358–76. DOI: https://doi.org/10.1016/j.annonc.2022.12.013

Gerber DE, Rasco DW, Le P, Yan J, Dowell JE, Xie Y. Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy. J Thorac Oncol. 2011;6:365–71. DOI: https://doi.org/10.1097/JTO.0b013e3181fff142

Auclin E, Benitez-Montanez J, Tagliamento M, Parisi F, Gorria T, Garcia-Campelo R, et al. Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer. Lung Cancer. 2023;178:116–22. DOI: https://doi.org/10.1016/j.lungcan.2023.02.002

Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:339–57. DOI: https://doi.org/10.1016/j.annonc.2022.12.009

Chen M, Li Q, Xu Y, Zhao J, Zhang L, Wei L, et al. Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis. Thorac Cancer. 2020;11:1955–62. DOI: https://doi.org/10.1111/1759-7714.13488

Cao W, Li AW, Ren SX, Chen XX, Li W, Gao GH, et al. Efficacy of first-line chemotherapy affects the second-line setting response in patients with advanced non-small cell lung cancer. Asian Pac J Cancer Prev. 2014;15:6799–804. DOI: https://doi.org/10.7314/APJCP.2014.15.16.6799

Lang D, Huemer F, Rinnerthaler G, Horner A, Wass R, Brehm E, et al. Therapy line and associated predictors of response to PD-1/PD-L1-inhibitor monotherapy in advanced non-small-cell lung cancer: a retrospective bi-centric cohort study. Target Oncol. 2019;14:707–17. DOI: https://doi.org/10.1007/s11523-019-00679-9

Bratova M, Skrickova J, Matusikova M, Hrabcova K, Havel L, Koubkova L, et al. Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer. J Cancer Res Clin Oncol. 2023;149:17123–31. DOI: https://doi.org/10.1007/s00432-023-05431-5

Julian C, Machado RJM, Girish S, Chanu P, Heinzmann D, Harbron C, et al. Real-world data prognostic model of overall survival in patients with advanced NSCLC receiving anti-PD-1/PD-L1 immune checkpoint inhibitors as second-line monotherapy. Cancer Rep (Hoboken). 2022;5:e1578. DOI: https://doi.org/10.1002/cnr2.1578

Lindqvist J, Jekunen A, Sihvo E, Johansson M, Andersén H. Effect of adherence to treatment guidelines on overall survival in elderly non-small-cell lung cancer patients. Lung Cancer. 2022;171:9–17. DOI: https://doi.org/10.1016/j.lungcan.2022.07.006

Paakkola NM, Lindqvist J, Jekunen A, Sihvo E, Johansson M, Andersén H. Impact of sex and age on adherence to guidelines in non-small cell lung cancer management. Cancer Treat Res Commun. 2023;34:100675. DOI: https://doi.org/10.1016/j.ctarc.2022.100675

Hettinger GCN, Long Q, Parikh RB. Real-world effectiveness of second-line therapies in advanced non-small cell lung cancer: insights from propensity-weighted comparative analyses of longitudinal EHR data. Clin Lung Cancer. 2026;27:227–36.e12. DOI: https://doi.org/10.1016/j.cllc.2025.09.010

Eide IJZ, Nilssen Y, Lund-Iversen M, Brustugun OT. Factors affecting outcome in resected EGFR-mutated lung cancer. Acta Oncol. 2022;61:749–56. DOI: https://doi.org/10.1080/0284186X.2022.2066984

Tryggvadóttir SÁ, Stefánsson GV, Birgisson H, Gunnarsson Ö, Guðbjartsson T, Harðardóttir H, et al. Targeted therapy in the treatment of lung cancer in Iceland 2010–2023. Acta Oncol. 2026;65:261–7. DOI: https://doi.org/10.2340/ao.v65.45118

Wataya H, Okamoto T, Maruyama R, Seto T, Yamazaki K, Tagawa T, et al. Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib. Lung Cancer. 2009;64:341–5. DOI: https://doi.org/10.1016/j.lungcan.2008.09.005

Inal A, Kaplan MA, Kucukoner M, Urakci Z, Karakus A, Isikdogan A. Prognostic factors for second-line treatment of advanced non-small-cell lung cancer: retrospective analysis at a single institution. Asian Pac J Cancer Prev. 2012;13:1281–4. DOI: https://doi.org/10.7314/APJCP.2012.13.4.1281

Garde-Noguera J, Martin-Martorell P, De Julián M, Perez-Altozano J, Salvador-Coloma C, García-Sanchez J, et al. Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients. Clin Transl Oncol. 2018;20:1072–9. DOI: https://doi.org/10.1007/s12094-017-1829-5

Rousseau A, Michiels S, Simon-Tillaux N, Lolivier A, Bonastre J, Planchard D, et al. Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study. Lancet Reg Health Eur. 2024;43:100970. DOI: https://doi.org/10.1016/j.lanepe.2024.100970

Sommervoll FÅ, Horndalsveen H, Sommervoll DE, Koivonen J, Halvorsen TO, Grønberg BH, et al. How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab? Acta Oncol. 2026;65:232–40. DOI: https://doi.org/10.2340/1651-226X.2026.45040